**10th Annual Physicians Education Day in Inborn Errors of Immunity**

June 22, 2025

**Purpose**

Primary immunodeficiency diseases (PID), also termed as Inborn errors of immunity (IEI) are not as rare as once considered. There are more than 500 IEI and more than 400 disease causing genes have been discovered. These disorders frequently present with recurrent infection (type of infections often suggest type of immune defects) affecting sinuses, lungs and GI tract, an often with allergies, autoimmune diseases (e.g. autoimmune cytopenia, autoimmune endocrine diseases, autoimmune neuropathy, and autoimmune rheumatological diseases), inflammatory diseases (including IBD and CD), and cancer. Various therapeutic measures include immunoglobulin replacement therapy, hematopoietic stem cells transplant, gene therapy and gene editing. These will be addressed by 9 faculty. Clinicians including internists, pediatricians, family practice, Infectious disease specialists, hematologists, pulmonologists, gastroenterologists, ENT specialists, rheumatologists and allergists would be benefited from this meeting. Ample time is slated for discussion.

**Target Audience**

Specialties – Pediatrics, Allergy/Immunology, Endocrinology, Neurology, Rheumatology

Professions – Physician, Medical Student, Resident Physician

**Activity Objectives**

1 Apply knowledge about Primary Immunodeficiency Diseases

2 Describe the working of the immune system, clinical features and complications of primary immunodeficiency diseases, and various treatment options including immunoglobulin, hematopoietic stem cell transplantation, and gene therapy

**Accreditation Statement**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, Irvine School of Medicine and Foundation of Primary Immunodeficiency Diseases (FPID).  The University of California, Irvine School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. to provide continuing medical education for physicians.

**Designation Statement**

The University of California, Irvine School of Medicine designates this Live Activity for a maximum of 4.50 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**California Assembly Bill 1195 and 241**

This activity is in compliance with California Assembly Bill 1195 and 241, which require CME activities with patient care components to include curriculum in the subjects of cultural and linguistic competency & implicit bias. It is the intent of AB 1195 and AB 241 to encourage physicians and surgeons, CME providers in the State of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population and reduce health disparities through appropriate professional development. Please see the CME website, <https://www.meded.uci.edu/CME/> for AB 1195 and AB 241 resources.



A close-up of a sign

AI-generated content may be incorrect.

ABIM
CME
MOC
Accredited

CME for
ABPath CC

Part 2
MOC
The American Board of Pediatrics

**Faculty & Planner Disclosures**

University of California, Irvine School of Medicine Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Ankita Gupta, Masters in Commerce , M.COM, MBA | Activity Coordinator | Nothing to disclose - 02/12/2025 |
| Yesim Yilmaz Demirdag, MD | Other Planning Committee Member | Nothing to disclose - 05/01/2025 |
| Sudhir Gupta, MD, PhD | Course Director, Faculty | Nothing to disclose - 02/12/2025 |
| Manish Butte, MD, PhD, FCIS | Faculty | Advisor-Grifols|Advisor-ADMA|Grant or research support-X4|Grant or research support-Pharming - 04/21/2025 |
| Alexandra Freeman, MD | Faculty | Nothing to disclose - 03/06/2025 |
| Hal Hoffman, MD | Faculty | Consulting Fee-Sobi|Consulting Fee-Novartis Corporation Pharmaceuticals|Consulting Fee-Ventyx|Grant or research support-Inapill - 03/10/2025 |
| Neena Kapoor , MD | Faculty | Nothing to disclose - 03/24/2025 |
| Troy Torgerson, MD, PhD | Faculty | Consulting Fee-Pharming Healthcare|Consulting Fee-Takeda Pharmaceuticals (Any division)|Grant or research support-Lilly (Any division) - 03/25/2025 |
| Shireen Guide, MD | Faculty | Independent Contractor (included contracted research)-Arcutis (Relationship has ended)|Independent Contractor (included contracted research)-Boehringer Ingelheim Pharmaceuticals, Inc.|Independent Contractor (included contracted research)-Incyte Corporation Incyte Corporation|Independent Contractor (included contracted research)-Dermavant|Independent Contractor (included contracted research)-Castle Biosciences|Independent Contractor (included contracted research)-Krystal biotech|Independent Contractor (included contracted research)-Novartis Corporation Pharmaceuticals|Independent Contractor (included contracted research)-Pfizer (Any division)|Independent Contractor (included contracted research)-Sanofi S.A.|Speakers Bureau-Krystal Biotech|Independent Contractor (included contracted research)-Jeune|Independent Contractor (included contracted research)-Castlecreek Biosciences|Independent Contractor (included contracted research)-TWI Biosciences - 05/01/2025 |
| Leman Yel, MD, FAAAAI, FACAAI, FAAP | Faculty | Paid consultant-Takeda Pharmaceuticals (Any division)|Stocks or stock options, excluding diversified mutual funds-Baxter International, Inc.|Stocks or stock options, excluding diversified mutual funds-Takeda Pharmaceuticals (Any division) - 03/06/2025 |
| Joseph Church, MD | Faculty | Nothing to disclose - 04/11/2025 |
| Charlotte Cunningham-Rundles, MD, PhD | Faculty | Advisor-Grifols|Advisor-Sanofi S.A.|Advisor|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Grifols - 05/05/2025 |

**Agenda**

**[INSERT AGENDA HERE MANUALLY]**

**Acknowledgement of Commercial Support**

No commercial support has been received for this activity.